Asimov and RevOpsis Therapeutics Sign Licensing Agreement for CHO Edge System

Asimov and RevOpsis Therapeutics Sign Licensing Agreement for CHO Edge System

11/19/24, 2:45 PM
Industry
biotechnology
manufacturing
Type
agreement
Asimov has announced a licensing agreement with RevOpsis Therapeutics for its CHO Edge System. RevOpsis will integrate the system in the development and commercialization of RO-104, a first-in-class fully modular tri-specific biologic designed for the treatment of retinal vascular diseases.

Company Info

Company
Asimov
Additional Info
Asimov is a synthetic biology company advancing the design and manufacture of therapeutics.